The European Patent Office (EPO) has granted a new CRISPR/Cas9 patent (EP 4 289 948) to Professor Charpentier, along with The Regents of the University of California and the University of Vienna (collectively known as CVC). The divisional patent includes broad independent claims covering single guide RNAs, modified DNA-targeting RNAs and the combination guide RNAs […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!